CD274 and head and neck squamous cell carcinoma: The overall survival (OS) of patients diagnosed with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) can be improved by targeting the PD-1:PD-L1 axis (1–4).